Eade Katherine A. 4

What Happened

• Katherine A. Eade, a director of Harvard Bioscience, was granted 16,556 restricted stock units (RSUs) on June 9, 2026. The RSUs were awarded at $0.00 per share (reporting value $0) and are recorded as an "A" (award/grant) transaction — not a purchase or sale.
• The award vests in full either immediately prior to the company’s next annual meeting or one year from the grant date, whichever occurs earlier. After the grant, the filing indicates beneficial ownership of 58,669 shares equivalent (16,556 RSUs + 42,113 common shares).

Key Details

• Transaction date: 2026-06-09; Filing date: 2026-06-12 (appears to be one business day late vs. the 2-business-day Form 4 deadline).
• Price: $0.00 per share; Shares awarded: 16,556 RSUs; Reported beneficial ownership after grant: 58,669 shares (16,556 RSUs + 42,113 common shares).
• Vesting condition: RSUs vest in full immediately before next annual meeting or one year from grant, whichever is earlier (see footnote F1).
• Footnote on prior holdings: Numbers were adjusted for a 10-for-1 reverse stock split on March 13, 2026 (prior reported figures were 110,000 RSUs and 311,126 shares pre-split).

Context

• This was an equity award (RSUs) to a director — not a market purchase or sale — and therefore does not directly signal buying or selling intent. The award increases reported beneficial ownership once vested but had no cash exchanged at grant.